


**Figure S1.** Missing pattern and proportions of extracted data from included studies.






*Note: Var1: Severity, Var2: Mortality, Var3: Fever, Var4: Cough, Var5: Sputum production, Var6: Sore throat, Var7: Myalgia, Var8: Fatigue, Var9: Dyspnoea, Var10: Headache, Var11: Nausea, Var12: diarrhoea, Var13: Setting, Var14: Ethnics, Var15: Data\_first, Var16: Data\_last, Var17: age (mean), Var18: age (median), Var19: Gender, Var20: Cardiac comorbidity, Var21: Hypertension, Var22: Diabetes mellitus, Var23: COPD, Var24: Smoking*

**Figure S2a**. Forest plot for the proportion of symptoms and outcomes in COVID-19 patients among different study design groups.



**Figure S2**b. Forest plot for the proportion of symptoms and outcomes in COVID-19 patients among different ethnicity groups.



**Figure S3a.** Forest plot of pooled mean white blood cell counts among severe and non-severe COVID-19 patients.

|  |  |
| --- | --- |
| **Severe COVID-19 group** | **Non-severe COVID-19 group** |
|  |  |

**Figure S3b.** Forest plot of pooled mean lymphocyte counts among severe and non-severe COVID-19 patients.

|  |  |
| --- | --- |
| **Severe COVID-19 group** | **Non-severe COVID-19 group** |
|  |  |

**Figure S4a.** Effect of stage of the outbreak in proportion of symptoms in COVID-19 patients.

|  |  |
| --- | --- |
| *Fever: 85% to 60% (p for trend <0.001)* | *Cough: 60% to 50% (p for trend <0.001)* |
|  |  |
| *Fatigue: 50% to 10% (p for trend <0.001)* | *Dyspnoea: 40% to 20% (p for trend <0.001)* |
|  |  |

**Figure S4b.**Effect of age in proportion of symptoms in COVID-19 patients.

|  |  |
| --- | --- |
| *Fever: 50% to 85% (p for trend <0.001)* | *Cough: 45% to 60% (p for trend <0.001)* |
|  |  |
| *Fatigue: 5% to 45% (p for trend <0.001)* | *Dyspnoea: 0% to 50% (p for trend <0.001)* |
|  |  |

**Figure S4c.** Effect of stage of the outbreak in proportion of symptoms in severe COVID-19 patients.

|  |  |
| --- | --- |
| Fever | Cough |
|  |  |
| Sputum production | Sore throat |
|  |  |
| Myalgia | Fatigue |
|  |  |


*Note: The size of each circle has represented the inverse of the square root of effect size for each study. Date was represented the beginning enrolled day for each study (From 2019/12/1 to 2020/1/31).*

**Figure S5.** Meta-regression results. Number inside presenting coefficients of the confounders including age, cardiac comorbidity, hypertension, diabetes mellitus (D.M.), chronic obstructive pulmonary disease (COPD), smoking and stage of the outbreak


Chart, treemap chart

Description automatically generated


**Figure S6-1.** Funnel plot of Egger's test to detecting publication bias for mortality.




**Figure S6-2.** Funnel plot by Egger's test to detecting publication bias for severity.




**Figure S6-3.** Funnel plot by Egger's test to detecting publication bias for fever.




**Figure S6-4.** Funnel plot by Egger's test to detecting publication bias for cough.




**Figure S6-5.** Funnel plot by Egger's test to detecting publication bias for sputum production.




**Figure S6-6.** Funnel plot by Egger's test to detecting publication bias for sore throat.




**Figure S6-7.** Funnel plot by Egger's test to detecting publication bias for myalgia.




**Figure S6-8.** Funnel plot by Egger's test to detecting publication bias for fatigue.




**Figure S6-9.** Funnel plot by Egger's test to detecting publication bias for dyspnoea.




**Figure S6-10.** Funnel plot by Egger's test to detecting publication bias for headache.



**Figure S6-11.** Funnel plot by Egger's test to detecting publication bias for nausea.



**Figure S6-12.** Funnel plot by Egger's test to detecting publication bias for diarrhoea.



**Figure S7a.** Graphical Display of quality assessment for cohort study.

A picture containing chart

Description automatically generated

**Figure S7b.** Graphical Display of quality assessment for case series study.

Graphical user interface

Description automatically generated

**Figure S7c.** Graphical Display of quality assessment for case control study.

A picture containing chart

Description automatically generated

**Table S1.** Search Strategy to Identify Relevant Articles.

|  |  |  |
| --- | --- | --- |
| S/N | Concept | Search Terms |
| #1 | Disease | ("Coronavirus"[Mesh] OR coronavirus disease[tw] OR coronavirus[tw] OR 2019-nCov[tw] OR SARS-CoV-2[tw] OR COVID-19[tw] OR new coronary pneumonia[tw] OR corona virus[tw] OR novel coronavirus[tw] OR nCov[tw] OR SARS-2-CoV[tw] OR wuhan coronavirus[tw] OR wuhan pneumonia[tw]) |
| #2 | Clinical, Laboratory, Radiologic Characteristics, and Outcomes | (symptom\*[tw] OR clinical characteristic\*[tw] OR co-morbidit\*[tw] OR comorbidit\*[tw] OR epidemiolog\*[tw] OR inciden\*[tw] OR "Radiology"[Mesh] OR radiologic features[tw] OR chest x-ray[tw] OR chest CT[tw] OR Lung ultrasound[tw] OR "Ultrasonography"[Mesh] OR "Tomography, X-Ray Computed"[Mesh] OR ultrasound[tw] OR sonography[tw] OR ultrasonography[tw] OR radiography[tw] OR chest film[tw] OR chest radiograph[tw] risk factors[tw] OR "Diagnosis"[Mesh] OR cases[tw] OR "Mortality"[Mesh] OR death[tw] OR case fatality rate[tw] OR case fatality ratio[tw] OR "Physical Examination"[Mesh] OR "Clinical Laboratory Techniques"[Mesh] OR "Diagnostic Tests, Routine"[Mesh] OR clinical laboratory [tw] OR laboratory characteristics [tw] OR laboratory panel [tw] OR laboratory values [tw] OR "Critical Care"[Mesh] OR "Intensive Care Units"[Mesh] OR Intensive Care Units[tw] OR "Hospitalization"[Mesh] OR "Sepsis"[Mesh]) |
| #3 | Publication period | ("2019/12/31"[PDAT] : "2020/03/31"[PDAT]) |
| #4 | Publication type | (Review[ptyp] OR Practice Guideline[ptyp] OR Letter[ptyp] OR Guideline[ptyp] OR Editorial[ptyp] OR Comment[ptyp]) |
| #5 | Species | animals[mh] NOT humans[mh] |
| #6 | #1 AND #2 AND #3 NOT #4 | |
| Strategy | #6 NOT #5 | |

**Table S2.** The National Institute of Health in the U.S. (NIH) Quality Assessment Tool**.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Study Design | Criteria | Yes | No | Unclear |
| Cohort Study | 1. Was the research question or objective in this paper clearly stated? |  |  |  |
| 2. Was the study population clearly specified and defined? |  |  |  |
| 3. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study pre-specified and applied uniformly to all participants? |  |  |  |
| 4. Was a sample size justification, power description, or variance and effect estimates provided? |  |  |  |
| 5. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? |  |  |  |
| 6. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? |  |  |  |
| 7. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? |  |  |  |
| 8. Were the outcome assessors blinded to the exposure status of participants? |  |  |  |
| 9. Was loss to follow-up after baseline 20% or less? |  |  |  |
| 10. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? |  |  |  |
| Case Series Study | 1. Was the study question or objective clearly stated? |  |  |  |
| 2. Was the study population clearly and fully described, including a case definition? |  |  |  |
| 3. Were the cases consecutive? |  |  |  |
| 4. Were the subjects comparable? |  |  |  |
| 5. Was the intervention clearly described? |  |  |  |
| 6. Were the outcome measures clearly defined, valid, reliable, and implemented consistently across all study participants? |  |  |  |
| 7. Was the length of follow-up adequate? |  |  |  |
| 8. Were the statistical methods well-described? |  |  |  |
| 9. Were the results well-described? |  |  |  |
| Case Control Study | 1. Was the research question or objective in this paper clearly stated and appropriate? |  |  |  |
| 2. Was the study population clearly specified and defined? |  |  |  |
| 3. Did the authors include a sample size justification? |  |  |  |
| 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? |  |  |  |
| 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? |  |  |  |
| 6. Were the cases clearly defined and differentiated from controls? |  |  |  |
| 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? |  |  |  |
| 8. Was there use of concurrent controls? |  |  |  |
| 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? |  |  |  |
| 10. Were the assessors of exposure/risk blinded to the case or control status of participants? |  |  |  |
| 11. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis? |  |  |  |

**Table S3.** Study characteristics of included studies.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Authors** | **Year** | **Country** | **Study Design** | **First date of**  **enrollment** | **Number of observations** | **Average of age** | **Severity (%)** | **Mortality (%)** | **Male (%)** | **Cardiac comorbidity (%)** | **Hypertension (%)** | **Diabetes mellitus (%)** | **COPD (%)** | **Smoking (%)** | **Symptoms** |
| Xia et al.1 | 2020 | China | Cohort | 2020/1/23 | 20 | NA | NA | NA | 65.0 | 30.0 | NA | NA | NA | NA | fever; cough; sore throat; fatigue; diarrhoea |
| Li et al.2 | 2020 | China | Cohort | 2020/1/23 | 51 | 58 | NA | NA | 54.9 | NA | NA | NA | NA | NA | fever; cough; fatigue |
| Zhu et al.3 | 2020 | China | Case control | 2019/12/1 | 12 | 52 | NA | NA | 66.7 | 16.7 | NA | NA | NA | NA | NA |
| Zhang et al.4 | 2020 | China | Cohort | 2020/1/16 | 120 | 57 | 48.3 | NA | 59.2 | 10.0 | 35.0 | 14.2 | 1.7 | 7.5 | fever; cough; fatigue; shortness of breath; nausea; diarrhoea |
| Yao et al.5 | 2020 | China | Cohort | 2020/1/21 | 40 | 53.87 | NA | NA | 60.0 | NA | NA | NA | NA | NA | fever; cough; sputum production; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Qin et al.6 | 2020 | China | Cohort | 2020/1/10 | 452 | 58 | 63.3 | NA | 52.0 | 6.0 | 29.9 | 16.6 | 2.7 | 1.5 | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Liu et al.7 | 2020 | China | Cohort | 2020/1/15 | 56 | 57.5 | NA | 5.4 | 55.4 | 5.4 | 17.9 | 7.1 | NA | 39.3 | fever; cough; sputum production; fatigue; shortness of breath |
| Chen et al.8 | 2020 | China | Cohort | 2020/1/20 | 249 | 51 | NA | 0.8 | 50.6 | 22.1 | NA | NA | NA | NA | fever; cough; sore throat; fatigue; shortness of breath; headache; diarrhoea |
| Bai et al.9 | 2020 | China | Case control | 2020/1/6 | 219 | 44.8 | NA | NA | 54.3 | 5.5 | 14.2 | 8.2 | 4.1 | NA | fever |
| Zhou et al.10 | 2020 | China | Cohort | 2019/12/29 | 191 | 56 | NA | 28.3 | 62.3 | 7.9 | 30.4 | 18.8 | 3.1 | 5.8 | fever; cough; sputum production; myalgia; fatigue; diarrhoea |
| Xu et al.11 | 2020 | China | Cohort | 2020/1/23 | 90 | 50 | NA | NA | 43.3 | 3.3 | 18.9 | 5.6 | 1.1 | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; headache; nausea; diarrhoea |
| Xie et al.12 | 2020 | China | Case Series | NA | 9 | 33 | NA | NA | 44.4 | NA | NA | NA | NA | NA | fever; cough; fatigue; diarrhoea |
| Korea Centers13 | 2020 | Korea & China | Cohort | 2020/1/20 | 28 | 42.6 | NA | NA | 53.6 | NA | NA | NA | NA | NA | sore throat; myalgia; headache |
| Tian et al.14 | 2020 | China | Cohort | 2020/1/20 | 262 | 47.5 | 17.6 | 1.2 | 48.5 | NA | NA | NA | NA | NA | fever; cough; fatigue; shortness of breath; headache |
| Peng et al.15 | 2020 | China | Cohort | 2020/1/20 | 112 | 62 | 14.3 | 15.2 | 47.3 | 55.4 | 82.1 | 20.5 | NA | NA | fever; cough; shortness of breath; diarrhoea |
| Guan et al.16 | 2020 | China | Case Series | 2020/1/22 | 7 | 50.37 | NA | NA | 42.9 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; headache; diarrhoea |
| Zhao et al.17 | 2020 | China | Case control | 2020/1/23 | 19 | 48 | NA | NA | 57.9 | NA | 10.5 | NA | NA | NA | fever; cough; sore throat; fatigue; headache; diarrhoea |
| Qiu et al.18 | 2020 | China | Case Series | 2020/2/2 | 8 | 26.142 | NA | NA | 50.0 | NA | NA | NA | NA | NA | fever; cough; sore throat; headache; diarrhoea |
| Wu et al.19 | 2020 | China | Cohort | 2020/1/21 | 40 | 45 | NA | 5.0 | 32.5 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; headache; nausea; diarrhoea |
| Yang et al.20 | 2020 | China | Cohort | 2020/1/17 | 149 | 45.11 | NA | NA | 54.4 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; shortness of breath; headache; nausea; diarrhoea |
| Chen et al.21 | 2020 | China | Cohort | 2020/1/14 | 29 | 56 | NA | 6.9 | 72.4 | NA | 27.6 | 17.2 | NA | 6.9 | fever; cough; sputum production; myalgia; fatigue; shortness of breath; headache; diarrhoea |
| Song et al.22 | 2020 | China | Cohort | 2020/1/20 | 51 | 49 | NA | NA | 49.0 | 2.0 | 9.8 | 5.9 | 2.0 | 5.9 | fever; cough; sputum production; sore throat; headache; nausea; diarrhoea |
| Huang et al.23 | 2020 | China | Cohort | 2019/12/16 | 40 | 49 | NA | 15.0 | 75.0 | 15.0 | 15.0 | 20.0 | 2.5 | 7.5 | fever; cough; sputum production; shortness of breath; headache; diarrhoea |
| Chung et al.24 | 2020 | China | Cohort | 2020/1/18 | 21 | 51 | NA | NA | 61.9 | NA | NA | NA | NA | NA | fever; cough; myalgia; fatigue; headache; nausea |
| Dai et al.25 | 2020 | China | Case Series | NA | 4 | 52.5 | NA | NA | 100.0 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; headache; diarrhoea |
| Ruan et al.26 | 2020 | China | Cohort | NA | 150 | 58.5 | NA | 45.3 | 68.0 | 8.7 | 34.7 | 16.7 | 2.0 | NA | fever; cough; sputum production; myalgia; fatigue; shortness of breath |
| Liu et al.27 | 2020 | China | Cohort | 2019/12/30 | 78 | 38 | NA | 2.6 | 50.0 | NA | 10.3 | 6.4 | 2.6 | 6.4 | fever; cough |
| Zhao et al.28 | 2020 | China | Cohort | NA | 101 | 44.44 | NA | NA | 55.5 | NA | NA | NA | NA | NA | fever; cough; sore throat; shortness of breath; nausea; diarrhoea |
| Zhang et al.29 | 2020 | China | Cohort | 2020/1/27 | 14 | 41 | NA | NA | 50.0 | NA | NA | NA | NA | NA | fever; cough; diarrhoea |
| Young et al.30 | 2020 | Singapore | Case Series | 2020/1/23 | 18 | 47 | NA | NA | 50.0 | NA | NA | NA | NA | NA | fever; cough; sore throat; shortness of breath; diarrhoea |
| Cao et al.31 | 2020 | China | Case Series | 2020/1/3 | 102 | 54 | NA | NA | 52.0 | 4.9 | 27.5 | 10.8 | NA | NA | fever; cough; myalgia; fatigue; diarrhoea |
| Wang et al.32 | 2020 | China | Cohort | 2020/1/25 | 31 | 7.08 | NA | NA | 48.4 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; fatigue; shortness of breath; diarrhoea |
| Li et al.33 | 2020 | China | Cohort | 2020/1/1 | 83 | 45.5 | 30.1 | NA | 53.0 | 1.2 | 6.0 | 8.4 | 6.0 | NA | fever; cough; sputum production; sore throat; myalgia; shortness of breath; headache; diarrhoea |
| Huang et al.34 | 2020 | China | Cohort | 2019/12/21 | 34 | 56.24 | NA | NA | 41.2 | 17.6 | 23.5 | 11.8 | 2.9 | NA | fever; cough; sputum production; shortness of breath; headache; diarrhoea |
| Wu et al.35 | 2020 | China | Cohort | 2020/1/22 | 80 | 46.1 | NA | NA | 48.8 | NA | NA | NA | 0.0 | NA | fever; cough; sore throat; myalgia; shortness of breath; headache; nausea; diarrhoea |
| Guan et al.36 | 2020 | China | Cohort | 2019/12/11 | 1081 | 47 | 16.0 | 2.8 | 58.9 | 2.5 | 15.3 | 7.5 | 1.1 | 14.6 | fever; cough; sputum production; sore throat; shortness of breath; headache; diarrhoea |
| Cai et al.37 | 2020 | China | Case Series | 2020/1/19 | 10 | 6.167 | NA | NA | 40.0 | NA | NA | NA | NA | NA | fever; cough; sore throat; shortness of breath; diarrhoea |
| Liu et al.38 | 2020 | China | Cohort | 2020/1/23 | 32 | 38.5 | NA | NA | 62.5 | 3.1 | 3.1 | NA | NA | NA | fever; cough |
| Li et al.39 | 2020 | China | Case control | 2020/1/1 | 31 | 54 | NA | NA | 48.4 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Bernheim et al.40 | 2020 | China | Cohort | 2020/1/18 | 121 | 45.3 | NA | NA | 50.4 | NA | NA | NA | NA | NA | fever; cough; sputum production |
| Bai et al.41 | 2020 | China | Case Series | 2020/1/26 | 6 | 49.5 | NA | NA | NA | NA | NA | NA | NA | NA | fever; sore throat |
| Liu et al.42 | 2020 | China | Case Series | 2020/1/11 | 12 | 53.67 | NA | NA | 66.7 | 33.3 | 25.0 | 16.7 | NA | NA | fever; cough; myalgia; headache; diarrhoea |
| Kui et al.43 | 2020 | China | Cohort | 2019/12/30 | 137 | 57 | NA | 11.7 | 44.5 | 7.3 | 9.5 | 10.2 | 1.5 | NA | fever; cough; sputum production; shortness of breath; headache; diarrhoea |
| Ren et al.44 | 2020 | China | Case Series | 2019/12/18 | 5 | 53.6 | NA | 20.0 | 60.0 | NA | 20.0 | NA | NA | NA | fever; cough; sputum production; myalgia; fatigue; shortness of breath; headache; diarrhoea |
| Yang et al.45 | 2020 | China | Cohort | 2019/12/24 | 52 | 59.7 | NA | 61.5 | 67.3 | 9.6 | NA | 17.3 | NA | 3.8 | fever; cough; myalgia; fatigue; shortness of breath; headache |
| Wu et al.46 | 2020 | China | Cohort | 2020/1/1 | 80 | 44 | NA | NA | 52.5 | 1.3 | 5.0 | 5.0 | 3.8 | 32.5 | fever; cough; sputum production; sore throat; myalgia; shortness of breath; headache; diarrhoea |
| Shi et al.47 | 2020 | China | Cohort | 2019/12/20 | 81 | 49.5 | NA | 3.7 | 51.9 | 9.9 | 14.8 | 12.3 | NA | NA | fever; cough; sputum production; fatigue; shortness of breath; headache; diarrhoea |
| Bai et al.48 | 2020 | China | Case Series | 2020/1/22 | 5 | 53.42 | NA | 20.0 | 60.0 | 20.0 | 20.0 | 40.0 | NA | NA | fever; cough; fatigue |
| Wang et al.49 | 2020 | China | Case Series | 2020/1/21 | 4 | 44.25 | NA | NA | 75.0 | NA | NA | NA | NA | NA | fever; cough; fatigue; headache |
| Wang et al.50 | 2020 | China | Case Series | 2020/1/1 | 138 | 56 | NA | NA | 54.4 | 14.5 | 31.2 | 10.1 | 2.9 | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Feng et al.51 | 2020 | China | Case Series | 2020/1/16 | 15 | 7.86 | NA | NA | 33.3 | NA | NA | NA | NA | NA | fever; cough; sore throat |
| Xie et al.52 | 2020 | China | Case Series | 2020/1/16 | 5 | 48.4 | NA | NA | 100.0 | NA | NA | NA | NA | NA | fever; cough; fatigue; shortness of breath |
| Xu et al.53 | 2020 | China | Case Series | 2020/1/10 | 62 | 41 | NA | NA | 56.5 | NA | 8.1 | 1.6 | 1.6 | NA | fever; cough; sputum production; headache; diarrhoea |
| Xiong et al.54 | 2020 | China | Cohort | 2020/1/11 | 42 | 49.5 | NA | NA | 59.5 | NA | NA | NA | NA | NA | fever; cough; fatigue; shortness of breath; diarrhoea |
| Zhou et al.55 | 2020 | China | Cohort | 2020/1/16 | 62 | 52.8 | NA | NA | 62.9 | NA | 6.5 | 6.5 | NA | NA | fever; cough; sputum production; myalgia; fatigue; shortness of breath |
| Xu et al.56 | 2020 | China | Case Series | 2020/1/22 | 10 | 7.543 | NA | NA | 60.0 | NA | NA | NA | NA | NA | fever; cough; sore throat; diarrhoea |
| Mo et al.57 | 2020 | China | Cohort | 2020/1/1 | 155 | 54 | NA | NA | 55.5 | NA | 23.9 | 9.7 | 3.2 | NA | fever; cough; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Cheng et al.58 | 2020 | China | Case control | 2020/1/19 | 11 | 50.36 | NA | NA | 72.7 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; shortness of breath; diarrhoea |
| Xu et al.59 | 2020 | China | Cohort | 2020/1/23 | 51 | 41.67 | NA | NA | 98.0 | NA | NA | 7.8 | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; diarrhoea |
| Wang et al.60 | 2020 | China | Cohort | 2020/1/16 | 69 | 42 | NA | 7.3 | 46.4 | NA | 13.0 | 10.1 | 5.8 | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; diarrhoea |
| Sun et al.61 | 2020 | China | Case Series | 2020/1/24 | 8 | 6.81 | NA | NA | 75.0 | NA | NA | NA | NA | NA | fever; cough; sputum production; myalgia; fatigue; headache; nausea; diarrhoea |
| Wang et al.62 | 2020 | China | Cohort | 2020/1/11 | 55 | 49 | NA | NA | 40.0 | NA | 14.5 | NA | NA | NA | fever; cough |
| Zhang et al.63 | 2020 | China | Case Series | 2020/1/21 | 4 | 52 | NA | NA | 25.0 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache |
| Lin et al.64 | 2020 | China | Cohort | 2020/1/20 | 92 | 41.5 | NA | NA | NA | NA | NA | NA | NA | NA | fever; cough; shortness of breath |
| Liu et al.65 | 2020 | China | Cohort | 2020/1/21 | 73 | 37.38 | 32.9 | NA | 56.2 | NA | NA | NA | NA | NA | fever; cough; sputum production; fatigue |
| Liu et al.66 | 2020 | China | Case Series | 2020/1/2 | 6 | 3.5 | NA | NA | 33.3 | NA | NA | NA | NA | NA | fever; cough |
| Han et al.67 | 2020 | China | Cohort | 2020/1/4 | 108 | 45 | NA | NA | 35.2 | NA | NA | NA | NA | NA | fever; cough; sore throat; myalgia; fatigue; headache; diarrhoea |
| Ki et al.68 | 2020 | Korea | Case Series | 2020/1/20 | 28 | 42 | NA | NA | 53.6 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; headache |
| Cai et al.69 | 2020 | China | Cohort | 2020/1/24 | 80 | 47 | NA | NA | 43.8 | NA | NA | NA | NA | NA | fever; cough; sore throat; headache; diarrhoea |
| He et al.70 | 2020 | China | Cohort | 2020/2/3 | 54 | 68 | NA | 48.2 | 63.0 | 14.8 | 44.4 | 24.1 | 3.7 | NA | fever; cough; myalgia; shortness of breath; diarrhoea |
| Zhu et al.71 | 2020 | China | Case control | 2020/1/24 | 32 | 40 | NA | NA | 46.9 | 15.6 | 68.8 | 31.3 | 18.8 | NA | fever; cough; sputum production; headache; diarrhoea |
| Pung et al.72 | 2020 | Singapore | Cohort | NA | 17 | 40 | NA | NA | 41.2 | NA | 5.9 | NA | NA | NA | fever; cough; sore throat; myalgia; shortness of breath; diarrhoea |
| Cheng et al.73 | 2020 | China | Cohort | 2020/1/28 | 615 | 63 | NA | 18.4 | 59.7 | NA | 37.9 | 16.3 | 2.1 | NA | fever |
| Liu et al.74 | 2020 | China | Case Series | 2020/1/22 | 10 | 42 | NA | NA | 40.0 | NA | 10.0 | NA | NA | NA | fever; cough; sputum production; sore throat; headache; nausea |
| Lu et al.75 | 2020 | China | Cohort | 2020/1/28 | 171 | 6.7 | NA | 0.6 | 60.8 | NA | NA | NA | NA | NA | fever; cough; sore throat; fatigue; diarrhoea |
| Chen et al.76 | 2020 | China | Case Series | NA | 9 | 42.11 | NA | NA | 55.6 | NA | NA | NA | NA | NA | fever; cough; diarrhoea |
| Cao et al.77 | 2020 | China | Cohort | 2020/1/18 | 199 | 58 | NA | NA | 60.3 | NA | NA | 11.6 | NA | NA | fever |
| Wang et al.78 | 2020 | China | Cohort | 2020/1/16 | 90 | 45 | NA | 2.2 | 36.7 | NA | NA | NA | NA | NA | fever; cough; sore throat; myalgia; fatigue; headache; diarrhoea |
| Zhao et al.79 | 2020 | China | Cohort | 2020/1/1 | 80 | 44 | NA | NA | 53.8 | NA | NA | NA | NA | NA | fever |
| Yuan et al.80 | 2020 | China | Cohort | 2020/1/1 | 27 | 60 | NA | 37.0 | 44.4 | NA | 18.5 | 22.2 | NA | NA | fever; cough; myalgia; shortness of breath |
| Arentz et al.81 | 2020 | American | Cohort | 2020/2/20 | 21 | 70 | NA | 52.4 | 52.4 | 52.4 | NA | 33.3 | 33.3 | NA | fever; cough; shortness of breath |
| Qiu et al.82 | 2020 | China | Case Series | 2020/2/4 | 10 | 65.7 | NA | NA | 0.0 | NA | 30.0 | 30.0 | NA | NA | fever; cough |
| Chu et al.83 | 2020 | China | Cohort | 2020/1/7 | 54 | 39 | 79.6 | NA | 66.7 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; nausea; diarrhoea |
| Qiang Ding et al.84 | 2020 | China | Case Series | NA | 5 | 50.2 | NA | NA | 40.0 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache |
| Hu et al.85 | 2020 | China | Case Series | 2020/1/28 | 24 | 32.5 | NA | NA | 33.3 | NA | NA | NA | NA | NA | fever; cough; fatigue |
| Li et al.86 | 2020 | China | Case Series | 2020/1/28 | 5 | 3.05 | NA | NA | 80.0 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat |
| Wang et al.87 | 2020 | China | Cohort | 2020/1/7 | 60 | 60 | NA | NA | 36.7 | NA | 15.0 | 10.0 | NA | NA | fever; cough; myalgia; shortness of breath |
| Wang et al.88 | 2020 | China | Cohort | 2020/1/1 | 339 | 71 | NA | 19.2 | 49.0 | NA | 40.7 | 15.9 | 6.2 | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Xu et al.89 | 2020 | China | Cohort | 2020/1/1 | 50 | 43.9 | 26.0 | NA | 58.0 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache |
| Zhang et al.90 | 2020 | China | Case Series | 2020/1/18 | 9 | 35.22 | NA | NA | 55.6 | NA | NA | 11.1 | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; diarrhoea |
| Zhou et al.91 | 2020 | China | Cohort | 2020/1/28 | 17 | 41.84 | 29.4 | NA | 35.3 | NA | NA | NA | NA | NA | fever; cough; fatigue; shortness of breath |
| Tolia et al.92 | 2020 | America | Cohort | 2020/3/10 | 29 | NA | NA | NA | 55.2 | NA | NA | NA | NA | NA | fever |
| Lo et al.93 | 2020 | China | Cohort | 2020/1/21 | 10 | 54 | NA | NA | 30.0 | NA | 30.0 | NA | NA | NA | fever; cough; sore throat; myalgia; shortness of breath; nausea; diarrhoea |
| Huang et al.94 | 2020 | China | Cohort | 2020/1/22 | 25 | 46.9 | NA | NA | 56.0 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue |
| Gou et al.95 | 2020 | China | Cohort | NA | 91 | NA | NA | NA | 42.9 | NA | NA | NA | NA | NA | fever; cough; fatigue |
| Escalera-Antezana et al.96 | 2020 | Bolivia | Case Series | 2020/3/2 | 12 | 36.5 | NA | NA | 50.0 | NA | 8.3 | NA | NA | NA | fever; cough; sore throat; myalgia; fatigue; headache; diarrhoea |
| Cao et al.97 | 2020 | China | Cohort | 2020/1/3 | 102 | 54 | NA | 16.7 | 52.0 | NA | 27.5 | 10.8 | NA | NA | fever; cough; myalgia; fatigue; diarrhoea |
| Cai et al.98 | 2020 | China | Cohort | 2020/1/11 | 298 | 47.5 | 19.5 | 1.0 | 48.7 | NA | 15.8 | 6.0 | NA | NA | fever; cough; sore throat; fatigue; headache; diarrhoea |
| Jin et al.99 | 2020 | China | Cohort | 2020/1/17 | 651 | 45.615 | NA | NA | 50.8 | NA | 15.4 | 7.4 | 0.2 | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Guo et al.100 | 2020 | China | Cohort | 2020/1/23 | 187 | 58.5 | NA | 23.0 | 48.7 | 11.2 | 32.6 | 15.0 | 2.1 | NA | NA |
| Guo et al.101 | 2020 | China | Cohort | 2020/2/10 | 174 | 59 | NA | 5.2 | 43.7 | NA | 24.7 | 21.3 | NA | NA | fever; cough; sore throat; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Chen et al.102 | 2020 | China | Case Series | 2020/1/13 | 274 | 62 | NA | NA | 62.4 | NA | 33.9 | 17.2 | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Bhatraju et al.103 | 2020 | USA | Case Series | 2020/2/24 | 24 | 64 | NA | 50.0 | 62.5 | NA | NA | 58.3 | 4.2 | NA | fever; cough; sputum production; sore throat; shortness of breath; headache |
| Chen et al.104 | 2020 | China | Cohort | 2019/12/15 | 21 | 56 | 52.4 | 19.1 | 81.0 | NA | 23.8 | 14.3 | NA | NA | fever; cough; sputum production; myalgia; fatigue; shortness of breath; headache; diarrhoea |
| Tang et al.105 | 2020 | China | Case control | 2019/12/24 | 73 | 62 | NA | NA | 61.6 | NA | 95.9 | 47.9 | NA | NA | fever; cough; sputum production; myalgia; fatigue; shortness of breath; nausea; diarrhoea |
| Yu et al.106 | 2020 | China | Cohort | 2019/12/30 | 12 | 66 | NA | 25.0 | 83.3 | NA | NA | NA | NA | NA | fever; cough; shortness of breath |
| Li et al.107 | 2020 | China | Cohort | 2020/1/18 | 78 | 44.6 | NA | NA | 48.7 | NA | 12.8 | 5.1 | 11.5 | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Iwasawa et al.108 | 2020 | Japan | Case Series | 2020/2/1 | 6 | 69 | NA | NA | 33.3 | NA | 16.7 | 16.7 | NA | NA | fever; fatigue |
| Wang et al.109 | 2020 | China | Case Series | NA | 5 | 57.6 | NA | NA | 60.0 | NA | 80.0 | 20.0 | NA | NA | fever; cough; fatigue; shortness of breath; diarrhoea |
| Lescure et al.110 | 2020 | China | Case Series | 2020/1/24 | 5 | 47 | NA | 20.0 | 60.0 | NA | 20.0 | NA | NA | NA | fever; cough; shortness of breath; diarrhoea |
| Zheng et al.111 | 2020 | China | Cohort | 2020/2/15 | 55 | 60.5 | 38.2 | NA | 43.6 | NA | NA | NA | NA | NA | fever; cough |
| Zhang et al.112 | 2020 | China | Case Series | 2020/2/5 | 7 | 59.85 | NA | 71.4 | 57.1 | NA | 42.9 | 28.6 | NA | NA | fever; cough; shortness of breath; diarrhoea |
| Zhang et al.113 | 2020 | China | Cohort | 2020/1/16 | 95 | 49 | 33.7 | NA | 55.8 | NA | NA | NA | NA | NA | fever |
| Yuan et al.114 | 2020 | China | Cohort | 2020/1/5 | 94 | 40 | 11.7 | NA | 44.7 | 6.4 | 9.6 | 5.3 | NA | NA | fever; cough; sore throat; fatigue; diarrhoea |
| Wu et al.115 | 2020 | China | Cohort | 2020/1/20 | 280 | 43.12 | 29.6 | NA | 53.9 | NA | NA | NA | 0.4 | NA | fever; cough; sore throat; myalgia; shortness of breath; headache; nausea; diarrhoea |
| Wong et al.116 | 2020 | China | Cohort | 2020/1/1 | 64 | 56 | NA | NA | 40.6 | NA | 20.3 | 12.5 | NA | NA | fever; cough; sputum production; sore throat; shortness of breath; diarrhoea |
| Qiu et al.117 | 2020 | China | Cohort | 2020/1/17 | 36 | 8.3 | NA | NA | 63.9 | NA | NA | NA | NA | NA | fever; cough; sore throat; headache |
| Zheng et al.118 | 2020 | China | Cohort | 2020/2/1 | 25 | 3 | NA | NA | 56.0 | NA | NA | NA | NA | NA | fever; cough; shortness of breath; diarrhoea |
| Zhang et al.119 | 2020 | China | Cohort | 2020/1/18 | 199 | 45.33 | NA | NA | 46.7 | NA | 50.3 | 24.1 | 0.5 | NA | fever |
| Zhang et al.120 | 2020 | China | Cohort | 2020/1/13 | 28 | 65 | NA | 28.6 | 60.7 | NA | NA | 14.3 | NA | NA | fever; cough; myalgia; fatigue; shortness of breath; diarrhoea |
| Zhou et al.121 | 2020 | China | Cohort | 2020/1/21 | 62 | 47.26 | NA | NA | 54.8 | NA | NA | NA | NA | NA | fever |
| Liu et al.122 | 2020 | China | Case Series | NA | 5 | 6.036 | NA | NA | 80.0 | NA | NA | NA | NA | NA | fever; cough; diarrhoea |
| Wang et al.123 | 2020 | China | Cohort | 2020/1/25 | 114 | 53 | NA | NA | 50.9 | NA | 28.9 | NA | NA | NA | fever; cough; sputum production; sore throat; shortness of breath; diarrhoea |
| Xie et al.124 | 2020 | China | Cohort | 2020/2/2 | 79 | 60 | 35.4 | NA | 55.7 | 8.9 | 17.7 | 10.1 | NA | NA | fever; cough; sputum production; shortness of breath; diarrhoea |
| Wan et al.125 | 2020 | China | Cohort | 2020/1/23 | 135 | 47 | 29.6 | 0.7 | 53.3 | NA | 9.6 | 8.9 | NA | NA | fever; cough; sputum production; sore throat; shortness of breath; headache; nausea; diarrhoea |
| Lu et al.126 | 2020 | China | Case Series | NA | 5 | 52.4 | NA | NA | 20.0 | NA | NA | NA | NA | NA | fever; cough; sputum production; fatigue; shortness of breath |
| Dong et al.127 | 2020 | China | Case Series | NA | 11 | 36.63 | NA | NA | 45.5 | NA | 9.1 | NA | 9.1 | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Albano et al.128 | 2020 | Italy | Case Series | 2020/3/16 | 7 | 64.57 | NA | NA | 28.6 | NA | NA | NA | NA | NA | fever; cough; sputum production; fatigue; shortness of breath |
| Zhu et al.129 | 2020 | China | Cohort | 2020/1/18 | 72 | 55.6 | NA | NA | 58.3 | NA | NA | NA | NA | NA | fever; cough; fatigue; shortness of breath |
| Yu et al.130 | 2020 | China | Case Series | 2020/1/21 | 4 | 74.25 | NA | 25.0 | 100.0 | NA | 25.0 | NA | 25.0 | NA | fever; cough |
| Pan et al.131 | 2020 | China | Cohort | 2020/1/12 | 21 | 40 | NA | NA | 28.6 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue |
| Chen et al.132 | 2020 | China | Case Series | 2020/1/1 | 99 | 55.5 | NA | 11.1 | 67.7 | NA | NA | 12.1 | NA | NA | fever; cough; sore throat; myalgia; shortness of breath; headache; nausea; diarrhoea |
| Chen et al.133 | 2020 | China | Case control | 2020/1/26 | 78 | 45 | NA | NA | 50.0 | NA | NA | 1.3 | NA | NA | fever; cough; sputum production; sore throat; fatigue; shortness of breath; headache; diarrhoea |
| Diao et al.134 | 2020 | China | Case Series | 2020/1/17 | 6 | 47.5 | NA | NA | 50.0 | NA | NA | NA | NA | NA | fever; cough; diarrhoea |
| Z. F. Chen et al.135 | 2020 | China | Cohort | 2020/1/20 | 98 | 43 | NA | NA | 53.1 | NA | NA | NA | NA | NA | fever; cough; sore throat; shortness of breath |
| Chan JF et al.136 | 2020 | China | Case Series | 2020/1/10 | 5 | 48 | NA | NA | 60.0 | NA | 40.0 | 20.0 | NA | NA | fever; cough; sputum production; sore throat; diarrhoea |
| Luo S et al.137 | 2020 | China | Case Series | 2020/1/1 | 183 | 53.8 | NA | 3.8 | 55.7 | NA | NA | NA | NA | NA | nausea; diarrhoea |
| Wu C et al.138 | 2020 | China | Cohort | 2019/12/25 | 201 | 51 | 41.8 | 21.9 | 63.7 | NA | 19.4 | 10.9 | NA | NA | fever; cough; shortness of breath |
| Li et al.139 | 2020 | China | Cohort | 2020/1/20 | 80 | 47.5 | 21.3 | 0.0 | 50.0 | 6.3 | 17.5 | 12.5 | 3.8 | NA | fever; cough; sputum production; myalgia; fatigue; shortness of breath; headache; diarrhoea |
| Chen et al.140 | 2020 | China | Cohort | 2020/1/27 | 296 | NA | 10.1 | 0.0 | 46.3 | NA | NA | NA | NA | NA | NA |
| Jing Liu et al.141 | 2020 | China | Cohort | 2020/1/5 | 40 | 48.7 | NA | 7.5 | 37.5 | NA | 15.0 | 15.0 | NA | 12.5 | fever; cough; sputum production; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Yang et al.142 | 2020 | China | Cohort | 2020/1/7 | 93 | 46.4 | NA | 0.0 | 60.2 | 14.0 | 24.7 | 22.6 | NA | NA | fever; cough |
| Gang et al.143 | 2020 | United States | Cohort | 2020/3/1 | 180 | NA | NA | NA | NA | 25.0 | 43.9 | 26.1 | 9.4 | NA | cough; sore throat; myalgia; shortness of breath; headache; diarrhoea |
| Chen et al.144 | 2020 | China | Cohort | 2020/1/23 | 143 | 45.13 | 25.2 | 0.7 | 51.1 | 3.5 | 11.9 | 7.0 | NA | NA | fever; cough; sore throat; myalgia; fatigue; shortness of breath; headache |
| Annemarie et al.145 | 2020 | British | Cohort | 2020/2/6 | 20133 | 72.9 | NA | 25.7 | 59.9 | 27.2 | NA | 18.1 | 15.5 | 4.2 | fever; cough; shortness of breath; nausea; diarrhoea |
| Giacomo et al.146 | 2020 | Italy | Cohort | 2020/2/20 | 1591 | 63 | NA | 25.5 | 82.0 | 14.0 | 32.0 | 11.3 | 2.6 | NA | NA |
| Safiya et al.147 | 2020 | America | Case Series | 2020/3/1 | 5700 | 63 | NA | 9.7 | 60.3 | 16.9 | 53.1 | 31.7 | 5.0 | 9.8 | fever |
| L YF et al.148 | 2020 | China | Cohort | NA | 50 | 50.4 | NA | NA | 56.0 | NA | 16.0 | 6.0 | NA | NA | fever; cough; sputum production; myalgia; fatigue; shortness of breath; headache; diarrhoea |
| W J et al.149 | 2020 | China | Cohort | 2020/1/19 | 52 | 44 | NA | NA | 55.8 | NA | NA | NA | NA | NA | fever; cough; myalgia; fatigue; headache |
| Li X et al.150 | 2020 | China | Case Series | 2020/1/26 | 12 | 37 | NA | NA | 66.7 | NA | 16.7 | NA | NA | 33.3 | fever; cough; myalgia; fatigue; headache; diarrhoea |
| Z FY et al.151 | 2020 | China | Cohort | NA | 30 | 50.17 | NA | NA | 60.0 | NA | NA | NA | NA | NA | fever; cough |
| Z YJ et al.152 | 2020 | China | Cohort | 20-Jan | 26 | 39.77 | NA | NA | 69.2 | NA | 15.4 | 11.5 | NA | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; diarrhoea |
| Sun HY et al.153 | 2020 | China | Cohort | 2020/1/21 | 88 | 48.52 | NA | NA | 55.7 | 6.8 | 25.0 | 11.4 | NA | NA | fever; cough; sputum production; sore throat; myalgia; headache |
| Cheng DZ et al.154 | 2020 | China | Cohort | 2020/1/1 | 54 | 60.1 | NA | NA | 53.7 | 13.0 | 38.9 | 18.5 | NA | NA | fever; cough; fatigue; shortness of breath |
| Xiang TX et al.155 | 2020 | China | Cohort | 2020/1/21 | 49 | 42.9 | 18.4 | NA | 67.4 | NA | 12.2 | 4.1 | NA | 6.1 | fever; cough; sputum production; sore throat; fatigue; diarrhoea |
| Xiong J et al.156 | 2020 | China | Cohort | 2020/1/17 | 89 | 53 | 34.8 | 7.9 | 46.1 | NA | 29.2 | 15.7 | 5.6 | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; nausea; diarrhoea |
| Fang L et al.157 | 2020 | China | Cohort | 2020/1/25 | 308 | NA | NA | 5.2 | 49.4 | NA | NA | NA | NA | NA | fever; cough; fatigue; diarrhoea |
| Cheng KB et al.158 | 2020 | China | Cohort | 2020/1/1 | 463 | 51 | 39.1 | NA | 52.7 | 6.0 | 23.1 | 8.6 | 4.1 | 4.5 | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; headache; diarrhoea |
| Chen T et al.159 | 2020 | China | Cohort | NA | 76 | 59.5 | NA | 4.0 | 52.6 | 6.6 | 30.3 | 17.1 | NA | NA | fever; cough; sore throat; myalgia; fatigue; nausea |
| Cheng JL et al.160 | 2020 | China | Cohort | NA | 1079 | 46 | NA | 1.0 | 53.1 | NA | NA | NA | NA | NA | fever; cough; sputum production; sore throat; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Xu S et al.161 | 2020 | China | Cohort | 2020/1/8 | 62 | 62.9 | NA | 22.6 | 62.9 | 17.7 | 41.9 | 14.5 | 8.1 | NA | fever; cough; sputum production; sore throat; myalgia; fatigue; shortness of breath; nausea; diarrhoea |
| Sun WW et al.162 | 2020 | China | Cohort | NA | 337 | NA | NA | NA | 47.8 | NA | NA | NA | NA | NA | fever; cough; sore throat; myalgia; fatigue; diarrhoea |
| SM Y et al.163 | 2020 | China | Cohort | 2020/1/21 | 40 | 39.9 | NA | NA | 65.0 | NA | NA | NA | NA | NA | fever; cough; sore throat; myalgia; fatigue; diarrhoea |
| COVID-19 National Incident Room Surveillance T164 | 2020 | Australia | Cohort | NA | 71 | NA | NA | 2.8 | NA | NA | NA | NA | NA | NA | fever; cough; sore throat; myalgia; shortness of breath; headache; nausea; diarrhoea |
| Lin M et al.165 | 2020 | Canadian | Cohort | 2020/1/20 | 135 | 28 | NA | NA | 43.7 | NA | NA | NA | NA | NA | fever; sore throat; fatigue |
| Du W et al.166 | 2020 | China | Cohort | 2020/1/23 | 67 | 34.1 | NA | NA | 47.8 | NA | NA | NA | NA | NA | fever; cough; sputum production; myalgia; fatigue; shortness of breath; headache; nausea; diarrhoea |
| Ma H et al.167 | 2020 | China | Cohort | 2020/1/21 | 158 | NA | NA | 0.0 | 26.6 | 5.1 | NA | NA | NA | NA | fever; cough; sore throat; diarrhoea |
| Li H et al.168 | 2020 | China | Cohort | 2020/1/24 | 40 | 5.09 | NA | NA | 57.5 | NA | NA | NA | NA | NA | fever; cough; sore throat; fatigue; diarrhoea |
| Song W et al.169 | 2020 | China | Case Series | 2020/1/1 | 16 | 8.5 | NA | NA | 62.5 | NA | NA | NA | NA | NA | fever; cough; sore throat |
| D YH et al.170 | 2020 | China | Case Series | 2020/1/27 | 7 | 40 | NA | NA | 57.1 | NA | NA | NA | NA | NA | fever; cough |
| Yaoling M et al.171 | 2020 | China | Cohort | NA | 115 | NA | NA | NA | 63.5 | NA | NA | NA | NA | NA | fever |
| Zhang B et al.172 | 2020 | China | Cohort | 2020/1/20 | 46 | 8.75 | NA | NA | 63.0 | NA | NA | NA | NA | NA | fever; cough |
| Xin T et al.173 | 2020 | China | Case Series | 2020/1/17 | 13 | 7.90769 | NA | NA | 30.8 | NA | NA | NA | NA | NA | fever; cough; diarrhoea |
| Wu Q et al.174 | 2020 | China | Cohort | 2020/1/20 | 74 | 6 | NA | 0.0 | 59.5 | NA | NA | NA | NA | NA | fever; cough; sputum production; myalgia; shortness of breath; headache; diarrhoea |
| Li B et al.175 | 2020 | China | Cohort | 2020/1/16 | 22 | 8 | NA | NA | 54.6 | NA | NA | NA | NA | NA | fever; cough |
| Parri N et al.176 | 2020 | Italy | Cohort | 2020/3/3 | 100 | 3.3 | NA | 0.0 | 57.0 | NA | NA | NA | NA | NA | fever; cough; sore throat; fatigue; shortness of breath; headache; diarrhoea |
| Garazzino S et al.177 | 2020 | Italy | Cohort | 2020/4/10 | 168 | 5 | NA | NA | 56.0 | NA | NA | NA | NA | NA | fever; cough; fatigue; shortness of breath; diarrhoea |
| COVID-19 National Emergency Response Center178 | 2020 | Korea | Cohort | 2020/1/20 | 7755 | 77 | NA | 0.9 | 0.5 | 0.1 | 0.4 | 0.3 | NA | NA | NA |
| Chang D et al.179 | 2020 | China | Case Series | 2020/1/16 | 13 | 34 | NA | NA | 76.9 | NA | NA | NA | NA | NA | fever; cough; sputum production; myalgia; headache; diarrhoea |
| Tan YP et al.180 | 2020 | China | Case Series | 2020/1/27 | 10 | 7 | NA | 0.0 | 30.0 | NA | NA | NA | NA | NA | fever; cough; sore throat |
| Cao et al.181 | 2020 | China | Cohort | 2020/1/1 | 128 | NA | 16.4 | NA | 46.9 | NA | NA | NA | NA | NA | fever; cough; sore throat |
| Feng et al.182 | 2020 | China | Cohort | 2020/1/1 | 476 | 50 | NA | 8.0 | 56.9 | 8.0 | 23.7 | 10.3 | 4.6 | 9.2 | fever; cough; sputum production; myalgia; shortness of breath |
| G L et al.183 | 2020 | China | Case Series | 2020/1/1 | 10 | 41.8 | NA | NA | 60.0 | NA | NA | NA | NA | NA | fever; cough; sore throat |
| Zheng et al.184 | 2020 | China | Cohort | 2020/1/17 | 161 | 45 | 18.6 | NA | 49.7 | 2.5 | 13.7 | 4.3 | 3.7 | NA | fever; cough; myalgia; fatigue; shortness of breath; headache; diarrhoea |
| Lian J et al.185 | 2020 | China | Cohort | 2020/1/17 | 788 | 45.83 | NA | NA | 51.8 | 1.4 | 16.0 | 7.2 | 0.4 | 6.9 | fever; cough; sputum production; sore throat; fatigue; shortness of breath; headache |
| Shi S et al.186 | 2020 | China | Cohort | 2020/1/20 | 416 | 64 | NA | 13.7 | 49.3 | 10.6 | 30.5 | 14.4 | 2.9 | NA | fever; cough; sputum production; sore throat; fatigue; shortness of breath; headache; diarrhoea |
| Yang S et al.187 | 2020 | China | Cohort | 2020/1/20 | 44 | 48.5 | NA | NA | 56.8 | NA | NA | NA | NA | NA | fever; cough; fatigue |
| Deng Y et al.188 | 2020 | China | Cohort | 2020/1/1 | 225 | NA | NA | 11.1 | 55.1 | 7.6 | 25.8 | 11.6 | NA | NA | fever; cough; sputum production; shortness of breath; headache; diarrhoea |

**Table S4. The pooled proportion of symptoms and outcomes in COVID-19 patients among the overall, different study design groups, different age groups, and different ethnicity groups.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Symptoms | Group | Number of Studies | Proportion  (95% C.I.) | Q | I2 | *p*-value |
| Mortality | **Overall** | 61 | 0.10 (0.06-0.14) | 6342.74 | 99.1% |  |
| **Study Design** | | | | | |
| Cohort | 51 | 0.09 (0.06-0.13) | 6213.29 | 99.2% | *0.101* |
| Case Series | 10 | 0.17 (0.05-0.33) | 49.49 | 81.8% |
| Case Control | 0 | NA | NA | NA |
| **Age of participant** | | | | | |
| Adult | 52 | 0.12 (0.08-0.17) | 5966.21 | 99.1% | ***<0.0001*** |
| Children | 4 | 0.00 (0.00-0.005) | 0.80 | 0.0% |
| **Ethnics** | | | | | |
| Chinese | 53 | 0.09 (0.06-0.13) | 1118.57 | 95.4% | *0.462* |
| Non-Chinese | 8 | 0.15 (0.03-0.32) | 4668.46 | 99.9% |
| Severity | **Overall** | 27 | 0.31 (0.25-0.37) | 548.58 | 95.3% |  |
| **Study Design** | | | | | |
| Cohort | 27 | 0.31 (0.25-0.37) | 548.58 | 95.3% | N.A. |
| Case Series | NA | NA | NA | NA |
| Case Control | NA | NA | NA | NA |
| **Age of participant** | | | | | |
| Adult | 25 | 0.31 (0.25-0.38) | 537.07 | 95.5% | N.A. |
| Children | NA | NA | NA | NA |
| **Ethics** | | | | | |
| Chinese | 27 | 0.31 (0.25-0.37) | 548.58 | 95.3% | NA |
| Non-Chinese | NA | NA | NA | NA |
| Fever | **Overall** | 182 | 0.76 (0.72-0.79) | 7618.08 | 97.6% |  |
| **Study Design** | | | | | |
| Cohort | 123 | 0.76 (0.73-0.79) | 3645.58 | 96.7% | *0.256* |
| Case Series | 52 | 0.73 (0.64-0.81) | 1663.15 | 96.9% |
| Case Control | 7 | 0.82 (0.72-0.91) | 56.11 | 89.3% |
| **Age of participant** | | | | | |
| Adult | 152 | 0.80 (0.77-0.83) | 7068.88 | 97.9% | ***<0.0001*** |
| Children | 20 | 0.52 (0.41-0.62) | 145.16 | 86.9% |
| **Ethics** | | | | | |
| Chinese | 167 | 0.78 (0.74-0.81) | 3951.68 | 95.8% | ***<0.0001*** |
| Non-Chinese | 15 | 0.53 (0.40-0.65) | 1984.65 | 99.3% |
| Cough | **Overall** | 169 | 0.56 (0.52-0.59) | 3778.37 | 95.6% |  |
| **Study Design** | | | | | |
| Cohort | 115 | 0.54 (0.50-0.58) | 3548.34 | 96.8% | ***0.006*** |
| Case Series | 48 | 0.61 (0.52-0.69) | 193.48 | 75.7% |
| Case Control | 6 | 0.72 (0.61-0.82) | 9.72 | 48.5% |
| **Age of participant** | | | | | |
| Adult | 140 | 0.57 (0.53-0.61) | 3071.04 | 95.5% | ***0.018*** |
| Children | 20 | 0.44 (0.34-0.54) | 57.80 | 67.1% |
| **Ethics** | | | | | |
| Chinese | 157 | 0.55 (0.52-0.59) | 3246.54 | 95.2% | *0.343* |
| Non-Chinese | 12 | 0.62 (0.49-0.74) | 138.82 | 92.1% |
| Sputum production | **Overall** | 75 | 0.24 (0.21-0.29) | 1486.46 | 95.0% |  |
| **Study Design** | | | | | |
| Cohort | 51 | 0.23 (0.19-0.28) | 1366.32 | 96.3% | *0.108* |
| Case Series | 19 | 0.27 (0.18-0.37) | 47.42 | 62.0% |
| Case Control | 5 | 0.37 (0.23-0.52) | 17.24 | 76.8% |
| **Age of participant** | | | | | |
| Adult | 70 | 0.25 (0.21-0.29) | 1453.37 | 95.3% | *0.514* |
| Children | 4 | 0.16 (0.01-0.41) | 16.57 | 81.9% |
| **Ethics** | | | | | |
| Chinese | 72 | 0.25 (0.21-0.29) | 1473.56 | 95.2% | *0.817* |
| Non-Chinese | 3 | 0.21 (0.02-0.50) | 12.62 | 84.2% |
| Sore throat | **Overall** | 85 | 0.12 (0.09-0.14) | 781.72 | 89.3% |  |
| **Study Design** | | | | | |
| Cohort | 58 | 0.10 (0.08-0.13) | 667.92 | 91.5% | ***0.003*** |
| Case Series | 23 | 0.20 (0.13-0.29) | 96.84 | 77.3% |
| Case Control | 4 | 0.12 (0.04-0.24) | 8.38 | 64.2% |
| **Age of participant** | | | | | |
| Adult | 69 | 0.11 (0.08-0.14) | 557.09 | 87.8% | *0.228* |
| Children | 10 | 0.17 (0.07-0.31) | 108.14 | 91.7% |
| **Ethics** | | | | | |
| Chinese | 76 | 0.10 (0.08-0.13) | 660.39 | 88.6% | ***0.011*** |
| Non-Chinese | 9 | 0.25 (0.14-0.38) | 58.69 | 86.4% |
| Myalgia | **Overall** | 75 | 0.19 (0.16-0.23) | 575.81 | 87.1% |  |
| **Study Design** | | | | | |
| Cohort | 55 | 0.18 (0.15-0.21) | 466.29 | 88.4% | ***0.0002*** |
| Case Series | 17 | 0.27 (0.19-0.35) | 40.61 | 60.6% |
| Case Control | 3 | 0.35 (0.26-0.46) | 0.83 | 0.0% |
| **Age of participant** | | | | | |
| Adult | 70 | 0.20 (0.17-0.24) | 460.93 | 85.0% | *0.091* |
| Children | 2 | 0.01 (0.00-0.23) | 3.90 | 74.4% |
| **Ethics** | | | | | |
| Chinese | 70 | 0.19 (0.16-0.23) | 533.54 | 87.1% | *0.584* |
| Non-Chinese | 5 | 0.23 (0.11-0.37) | 25.01 | 84.0% |
| Fatigue | **Overall** | 94 | 0.29 (0.25-0.33) | 2157.66 | 95.7% |  |
| **Study Design** | | | | | |
| Cohort | 68 | 0.28 (0.23-0.33) | 1806.42 | 96.3% | *0.203* |
| Case Series | 22 | 0.35 (0.25-0.44) | 91.01 | 76.9% |
| Case Control | 4 | 0.38 (0.14-0.66) | 41.30 | 92.7% |
| **Age of participant** | | | | | |
| Adult | 84 | 0.31 (0.27-0.35) | 1681.59 | 95.1% | ***<0.0001*** |
| Children | 6 | 0.06 (0.03-0.10) | 12.96 | 61.4% |
| **Ethics** | | | | | |
| Chinese | 87 | 0.30 (0.26-0.35) | 2037.29 | 95.8% | ***0.004*** |
| Non-Chinese | 7 | 0.12 (0.04-0.23) | 35.59 | 83.1% |
| Dyspnoea | **Overall** | 95 | 0.24 (0.20-0.29) | 8293.53 | 98.9% |  |
| **Study Design** | | | | | |
| Cohort | 75 | 0.22 (0.18-0.27) | 8177.59 | 99.1% | *0.084* |
| Case Series | 16 | 0.36 (0.20-0.53) | 74.37 | 79.8% |
| Case Control | 4 | 0.39 (0.16-0.65) | 30.78 | 90.3% |
| **Age of participant** | | | | | |
| Adult | 86 | 0.25 (0.21-0.30) | 7769.77 | 98.9% | ***<0.0001*** |
| Children | 6 | 0.05 (0.01-0.10) | 10.82 | 53.8% |
| **Ethics** | | | | | |
| Chinese | 85 | 0.23 (0.18-0.27) | 2498.05 | 96.6% | *0.202* |
| Non-Chinese | 10 | 0.38 (0.16-0.62) | 535.92 | 98.3% |
| Headache | **Overall** | 76 | 0.10 (0.08-0.12) | 465.78 | 83.9% |  |
| **Study Design** | | | | | |
| Cohort | 53 | 0.09 (0.08-0.11) | 399.19 | 87.0% | *0.071* |
| Case Series | 19 | 0.13 (0.07-0.19) | 42.01 | 57.2% |
| Case Control | 4 | 0.13 (0.05-0.24) | 7.19 | 58.3% |
| **Age of participant** | | | | | |
| Adult | 69 | 0.10 (0.08-0.12) | 441.14 | 84.6% | ***0.048*** |
| Children | 4 | 0.04 (0.005-0.09) | 2.93 | 0.0% |
| **Ethics** | | | | | |
| Chinese | 70 | 0.10 (0.08-0.12) | 446.60 | 84.5% | *0.99* |
| Non-Chinese | 6 | 0.10 (0.05-0.16) | 14.88 | 66.4% |
| Nausea | **Overall** | 36 | 0.09 (0.05-0.14) | 2176.27 | 98.4% |  |
| **Study Design** | | | | | |
| Cohort | 27 | 0.06 (0.04-0.09) | 1845.77 | 98.6% | ***0.008*** |
| Case Series | 7 | 0.21 (0.04-0.45) | 321.15 | 98.1% |
| Case Control | 2 | 0.27 (0.10-0.48) | 4.60 | 78.3% |
| **Age of participant** | | | | | |
| Adult | 34 | 0.09 (0.05-0.13) | 2148.13 | 98.5% | ***0.007*** |
| Children | 1 | 0.5 (0.15-0.85) | 0.00 | NA |
| **Ethics** | | | | | |
| Chinese | 34 | 0.09 (0.05-0.14) | 715.09 | 95.4% | *0.767* |
| Non-Chinese | 2 | 0.13 (0.00-0.43) | 36.32 | 97.2% |
| Diarrhoea | **Overall** | 110 | 0.10 (0.08-0.12) | 2885.30 | 96.2% |  |
| **Study Design** | | | | | |
| Cohort | 75 | 0.09 (0.07-0.11) | 2728.63 | 97.3% | ***0.003*** |
| Case Series | 29 | 0.16 (0.10-0.22) | 124.58 | 77.5% |
| Case Control | 6 | 0.11 (0.04-0.22) | 29.38 | 83.0% |
| **Age of participant** | | | | | |
| Adult | 91 | 0.10 (0.07-0.12) | 2648.50 | 96.6% | *0.946* |
| Children | 12 | 0.09 (0.04-0.15) | 16.57 | 33.6% |
| **Ethics** | | | | | |
| Chinese | 102 | 0.09 (0.07-0.11) | 860.88 | 88.3% | ***0.004*** |
| Non-Chinese | 8 | 0.18 (0.13-0.24) | 49.87 | 86.0% |

**Table S5.** Sensitivity analysis of outlier's analysis and publication bias.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Symptoms | Number of Studies | Pooled proportion before remove outlier | Number of removed Studies | Pooled proportion  after remove outlier | Publication bias  (Egger's test) |
| Mortality | 61 | 0.10 (0.06-0.14) | 31 | 0.09 (0.07-0.12) | p=0.145 |
| Fever | 182 | 0.76 (0.72-0.79) | 82 | 0.78 (0.76-0.80) | p<0.05 |
| Cough | 169 | 0.56 (0.52-0.59) | 68 | 0.55 (0.52-0.58) | p<0.05 |
| Sputum production | 75 | 0.24 (0.21-0.29) | 25 | 0.24 (0.21-0.27) | p=0.270 |
| Sore throat | 85 | 0.12 (0.09-0.14) | 23 | 0.11 (0.09-0.13) | p<0.05 |
| Myalgia | 75 | 0.19 (0.16-0.23) | 22 | 0.20 (0.17-0.22) | p<0.05 |
| Fatigue | 94 | 0.29 (0.25-0.33) | 38 | 0.29 (0.26-0.32) | p<0.05 |
| Dyspnoea | 95 | 0.24 (0.20-0.29) | 49 | 0.24 (0.21-0.27) | p<0.05 |
| Headache | 76 | 0.10 (0.08-0.12) | 12 | 0.10 (0.08-0.11) | p<0.05 |
| Nausea | 36 | 0.09 (0.05-0.14) | 12 | 0.07 (0.05-0.10) | p<0.05 |
| Diarrhoea | 110 | 0.10 (0.08-0.12) | 26 | 0.09 (0.08-0.11) | p<0.05 |

**Table S6.** Sensitivity analysis of different thresholds for fever. Each study could report results from more than one threshold

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Definition | Number of Studies | Proportion (%, 95% C.I.) | Q | I2 |
| Without temperature | 126 | 76 (72-80) | 6362.54 | 98.0% |
| Temperature >37.3oC | 42 | 75 (68-81) | 444.94 | 90.8% |
| Temperature >38oC | 47 | 45 (38-52) | 979.58 | 95.3% |
| Temperature >39oC | 35 | 16 (11-22) | 525.80 | 93.5% |

**Table S7.** Sensitivity analysis of different transformation methods.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Symptoms | Number of Studies | Raw proportion (P.R.) | Logit transformed (PLO) | Arcsine transformation (PAS) | Freeman-Tukey double arcsine transform (PFT) | GLMM |
| Mortality | 61 | 0.13 (0.09-0.17) | 0.08 (0.06-0.12) | 0.10 (0.07-0.14) | 0.10 (0.06-0.14) | 0.07 (0.04-0.10) |
| Fever | 182 | 0.74 (0.71-0.77) | 0.76 (0.73-0.79) | 0.76 (0.73-0.79) | 0.76 (0.72-0.79) | 0.77 (0.74-0.80) |
| Cough | 169 | 0.56 (0.53-0.59) | 0.56 (0.52-0.59) | 0.56 (0.52-0.60) | 0.56 (0.52-0.59) | 0.56 (0.52-0.60) |
| Sputum production | 75 | 0.26 (0.22-0.30) | 0.24 (0.20-0.29) | 0.25 (0.21-0.29) | 0.24 (0.21-0.29) | 0.23 (0.19-0.28) |
| Sore throat | 85 | 0.13 (0.10-0.15) | 0.12 (0.10-0.15) | 0.12 (0.10-0.15) | 0.12 (0.09-0.14) | 0.11 (0.09-0.14) |
| Myalgia | 75 | 0.21 (0.17-0.24) | 0.20 (0.17-0.23) | 0.20 (0.17-0.23) | 0.19 (0.16-0.23) | 0.19 (0.16-0.22) |
| Fatigue | 94 | 0.30 (0.26-0.34) | 0.28 (0.24-0.33) | 0.29 (0.25-0.33) | 0.29 (0.25-0.33) | 0.27 (0.23-0.32) |
| Dyspnoea | 95 | 0.27 (0.22-0.31) | 0.23 (0.18-0.28) | 0.25 (0.20-0.29) | 0.24 (0.20-0.29) | 0.22 (0.17-0.27) |
| Headache | 76 | 0.10 (0.09-0.12) | 0.10 (0.09-0.12) | 0.10 (0.09-0.12) | 0.10 (0.08-0.12) | 0.10 (0.08-0.12) |
| Nausea | 36 | 0.11 (0.06-0.16) | 0.08 (0.05-0.12) | 0.09 (0.06-0.14) | 0.09 (0.05-0.14) | 0.07 (0.05-0.11) |
| Diarrhoea | 110 | 0.11 (0.09-0.13) | 0.10 (0.08-0.12) | 0.10 (0.08-0.12) | 0.10 (0.08-0.12) | 0.09 (0.08-0.11) |

**Table S8**. The pooled proportion of symptoms in COVID-19 patients among the subgroup according to the criteria Q6 of the cohort study quality assessment.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Symptoms | Subgroup | Number of Studies | Proportion (95% C.I.) | Q | I2 | *p*-value |
| Fever | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 5 | 0.46 (0.22-0.71) | 414.78 | 99.0% | **0.015** |
| No | 65 | 0.77 (0.73-0.81) | 1273.35 | 95.0% |
| Cough | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 3 | 0.59 (0.44-0.73) | 26.34 | 92.4% | **0.351** |
| No | 62 | 0.51 (0.46-0.57) | 2338.47 | 97.4% |
| Sputum production | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 0 | N.A. | N.A. | N.A. | **NA** |
| No | 31 | 0.20 (0.14-0.26) | 1044.85 | 97.1% |
| Sore throat | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 2 | 0.08 (0.01-0.21) | 4.48 | 77.7% | **0.715** |
| No | 35 | 0.10 (0.08-0.13) | 244.29 | 86.1% |
| Myalgia | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 1 | 0.30 (0.17-0.45) | 0.00 | NA | **0.064** |
| No | 30 | 0.17 (0.12-0.22) | 315.01 | 90.8% |
| Fatigue | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 2 | 0.19 (0.02-0.45) | 10.36 | 90.3% | **0.564** |
| No | 42 | 0.26 (0.20-0.32) | 1352.84 | 97.0% |
| Dyspnoea | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 2 | 0.39 (0.00-0.94) | 174.47 | 99.4% | **0.488** |
| No | 12 | 0.18 (0.07-0.32) | 1130.08 | 99.0% |
| Headache | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 1 | 0.04 (0.01-0.09) | 0.00 | NA | **0.020** |
| No | 31 | 0.10 (0.08-0.13) | 275.96 | 89.1% |
| Nausea | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 0 | N.A. | N.A. | N.A. | **NA** |
| No | 15 | 0.06 (0.03-0.10) | 53.49 | 73.8% |
| Diarrhoea | **Q6. Prospectively measured exposure** | | | | | |
| Yes | 2 | 0.08 (0.03-0.13) | 0.46 | 0.0% | **0.487** |
| No | 40 | 0.10 (0.07-0.13) | 398.90 | 90.2% |

**Table S9**. The pooled proportion of symptoms in COVID-19 patients among the subgroup according to the criteria Q8 of the cohort study quality assessment.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Symptoms | Subgroup | Number of Studies | Proportion (95% C.I.) | Q | I2 | *p*-value |
| Fever | **Q8. Use of concurrent controls** | | | | | |
| Yes | 4 | 0.81 (0.72-0.89) | 0.82 | 0.0% | **0.0087** |
| No | 2 | 0.61 (0.49-0.72) | 2.16 | 53.6% |
| Cough | **Q8. Use of concurrent controls** | | | | | |
| Yes | 4 | 0.66 (0.51-0.80) | 5.85 | 48.7% | **0.86** |
| No | 1 | 0.68 (0.52-0.81) | 0.00 | NA |
| Sputum production | **Q8. Use of concurrent controls** | | | | | |
| Yes | 0 | N.A. | N.A. | N.A. | **NA** |
| No | 3 | 0.31 (0.12-0.54) | 9.34 | 78.6% |
| Sore throat | **Q8. Use of concurrent controls** | | | | | |
| Yes | 3 | 0.19 (0.09-0.31) | 0.79 | 0.0% | **0.0304** |
| No | 1 | 0.05 (0.0009-0.14) | 0.00 | NA |
| Myalgia | **Q8. Use of concurrent controls** | | | | | |
| Yes | 2 | 0.37 (0.21-0.55) | 0.64 | 0.0% | **NA** |
| No | 0 | N.A. | N.A. | N.A. |
| Fatigue | **Q8. Use of concurrent controls** | | | | | |
| Yes | 2 | 0.34 (0.001-0.84) | 13.84 | 92.8% | **0.278** |
| No | 1 | 0.10 (0.02-0.22) | 0.00 | NA |
| Dyspnoea | **Q8. Use of concurrent controls** | | | | | |
| Yes | 1 | 0.09 (0.00-0.35) | N.A. | N.A. | **NA** |
| No | 0 | N.A. | N.A. | N.A. |
| Headache | **Q8. Use of concurrent controls** | | | | | |
| Yes | 3 | 0.12 (0.02-0.28) | 6.96 | 71.2% | **NA** |
| No | 0 | N.A. | N.A. | N.A. |
| Nausea | **Q8. Use of concurrent controls** | | | | | |
| Yes | 1 | 0.16 (0.05-0.31) | N.A. | N.A. | **NA** |
| No | 0 | N.A. | N.A. | N.A. |
| Diarrhoea | **Q8. Use of concurrent controls** | | | | | |
| Yes | 4 | 0.06 (0.01-0.13) | 1.27 | 0.0% | **0.708** |
| No | 1 | 0.05 (0.0009-0.14) | 0.00 | NA |

**References-Supplement**

1. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. *Pediatr Pulmonol* 2020; **55**(5): 1169-74.

2. Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management. *AJR Am J Roentgenol* 2020; **214**(6): 1280-6.

3. Zhu ZW, Tang JJ, Chai XP, et al. [Comparison of heart failure and COVID-19 in chest CT features and clinical characteristics]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2020; **48**(6): 467-71.

4. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020; **75**(7): 1730-41.

5. Yao N, Wang SN, Lian JQ, et al. [Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region]. *Zhonghua Gan Zang Bing Za Zhi* 2020; **28**(3): 234-9.

6. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 2020; **71**(15): 762-8.

7. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. *J Infect* 2020; **80**(6): e14-e8.

8. Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. *J Infect* 2020; **80**(5): e1-e6.

9. Bai HX, Hsieh B, Xiong Z, et al. Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT. *Radiology* 2020; **296**(2): E46-E54.

10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**(10229): 1054-62.

11. Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *Eur J Nucl Med Mol Imaging* 2020; **47**(5): 1275-80.

12. Xie C, Jiang L, Huang G, et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. *Int J Infect Dis* 2020; **93**: 264-7.

13. Covid-19 National Emergency Response Center E, Case Management Team KCfDC, Prevention. Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea. *Osong Public Health Res Perspect* 2020; **11**(1): 8-14.

14. Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. *J Infect* 2020; **80**(4): 401-6.

15. Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2020; **48**(6): 450-5.

16. Guan Q, Liu M, Zhuang YJ, et al. [Epidemiological investigation of a family clustering of COVID-19]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; **41**(5): 629-33.

17. Zhao D, Yao F, Wang L, et al. A Comparative Study on the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia With Other Pneumonias. *Clin Infect Dis* 2020; **71**(15): 756-61.

18. Qiu YY, Wang SQ, Wang XL, et al. [Epidemiological analysis on a family cluster of COVID-19]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; **41**(4): 494-7.

19. Wu WS, Li YG, Wei ZF, et al. [Investigation and analysis on characteristics of a cluster of COVID-19 associated with exposure in a department store in Tianjin]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; **41**(4): 489-93.

20. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. *J Infect* 2020; **80**(4): 388-93.

21. Chen L, Liu HG, Liu W, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. *Zhonghua Jie He He Hu Xi Za Zhi* 2020; **43**(3): 203-8.

22. Song F, Shi N, Shan F, et al. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. *Radiology* 2020; **295**(1): 210-7.

23. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**(10223): 497-506.

24. Chung M, Bernheim A, Mei X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). *Radiology* 2020; **295**(1): 202-7.

25. Dai WC, Zhang HW, Yu J, et al. CT Imaging and Differential Diagnosis of COVID-19. *Can Assoc Radiol J* 2020; **71**(2): 195-200.

26. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020; **46**(5): 846-8.

27. Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J (Engl)* 2020; **133**(9): 1032-8.

28. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. *AJR Am J Roentgenol* 2020; **214**(5): 1072-7.

29. Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. *J Med Virol* 2020; **92**(6): 680-2.

30. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. *JAMA* 2020; **323**(15): 1488-94.

31. Cao J, Hu X, Cheng W, Yu L, Tu WJ, Liu Q. Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. *Intensive Care Med* 2020; **46**(5): 851-3.

32. Wang D, Ju XL, Xie F, et al. [Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China]. *Zhonghua Er Ke Za Zhi* 2020; **58**(4): 269-74.

33. Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. *Invest Radiol* 2020; **55**(6): 327-31.

34. Huang Y, Tu M, Wang S, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. *Travel Med Infect Dis* 2020; **36**: 101606.

35. Wu J, Liu J, Zhao X, et al. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. *Clin Infect Dis* 2020; **71**(15): 706-12.

36. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**(18): 1708-20.

37. Jiehao C, Jin X, Daojiong L, et al. A Case Series of Children With 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features. *Clin Infect Dis* 2020; **71**(6): 1547-51.

38. Liu C, Jiang ZC, Shao CX, et al. [Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study]. *Zhonghua Gan Zang Bing Za Zhi* 2020; **28**(2): 107-11.

39. Li YY, Wang WN, Lei Y, et al. [Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with coronavirus disease 2019]. *Zhonghua Jie He He Hu Xi Za Zhi* 2020; **43**(5): 427-30.

40. Bernheim A, Mei X, Huang M, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. *Radiology* 2020; **295**(3): 200463.

41. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA* 2020; **323**(14): 1406-7.

42. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci* 2020; **63**(3): 364-74.

43. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)* 2020; **133**(9): 1025-31.

44. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. *Chin Med J (Engl)* 2020; **133**(9): 1015-24.

45. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; **8**(5): 475-81.

46. Wu J, Wu X, Zeng W, et al. Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features. *Invest Radiol* 2020; **55**(5): 257-61.

47. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020; **20**(4): 425-34.

48. Bai SL, Wang JY, Zhou YQ, et al. [Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province]. *Zhonghua Yu Fang Yi Xue Za Zhi* 2020; **54**(0): E005.

49. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. *Biosci Trends* 2020; **14**(1): 64-8.

50. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**(11): 1061-9.

51. Feng K, Yun YX, Wang XF, et al. [Analysis of CT features of 15 Children with 2019 novel coronavirus infection]. *Zhonghua Er Ke Za Zhi* 2020; **58**(0): E007.

52. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical Coronavirus Disease 2019 (COVID-19) Pneumonia: Relationship to Negative RT-PCR Testing. *Radiology* 2020; **296**(2): E41-E5.

53. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020; **368**: m606.

54. Xiong Y, Sun D, Liu Y, et al. Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes. *Invest Radiol* 2020; **55**(6): 332-9.

55. Zhou S, Wang Y, Zhu T, Xia L. CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China. *AJR Am J Roentgenol* 2020; **214**(6): 1287-94.

56. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med* 2020; **26**(4): 502-5.

57. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis* 2020.

58. Cheng Z, Lu Y, Cao Q, et al. Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China. *AJR Am J Roentgenol* 2020; **215**(1): 121-6.

59. Xu T, Chen C, Zhu Z, et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. *Int J Infect Dis* 2020; **94**: 68-71.

60. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis* 2020; **71**(15): 769-77.

61. Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. *World J Pediatr* 2020; **16**(3): 251-9.

62. Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China. *J Infect Dis* 2020; **221**(11): 1770-4.

63. Zhang Q, Pan J, Zhao MX, Lu YQ. Clinical value of the emergency department in screening and diagnosis of COVID-19 in China. *J Zhejiang Univ Sci B* 2020; **21**(5): 388-93.

64. Lin D, Liu L, Zhang M, et al. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients. *Sci China Life Sci* 2020; **63**(4): 606-9.

65. Liu KC, Xu P, Lv WF, et al. CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity. *Eur J Radiol* 2020; **126**: 108941.

66. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. *N Engl J Med* 2020; **382**(14): 1370-1.

67. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. *AJR Am J Roentgenol* 2020; **215**(2): 338-43.

68. Ki M, Task Force for -nCo V. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. *Epidemiol Health* 2020; **42**: e2020007.

69. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering (Beijing)* 2020.

70. He XW, Lai JS, Cheng J, et al. [Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2020; **48**(6): 456-60.

71. Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. *J Med Virol* 2020.

72. Pung R, Chiew CJ, Young BE, et al. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. *Lancet* 2020; **395**(10229): 1039-46.

73. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int* 2020; **97**(5): 829-38.

74. Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. *Int J Infect Dis* 2020; **95**: 183-91.

75. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. *N Engl J Med* 2020; **382**(17): 1663-5.

76. Chen Q, Quan B, Li X, et al. A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019. *J Med Virol* 2020; **92**(6): 683-7.

77. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* 2020; **382**(19): 1787-99.

78. Wang Y, Dong C, Hu Y, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology* 2020; **296**(2): E55-E64.

79. Zhao X, Liu B, Yu Y, et al. The characteristics and clinical value of chest CT images of novel coronavirus pneumonia. *Clin Radiol* 2020; **75**(5): 335-40.

80. Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. *PLoS One* 2020; **15**(3): e0230548.

81. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA* 2020; **323**(16): 1612-4.

82. Qiu L, Liu X, Xiao M, et al. SARS-CoV-2 Is Not Detectable in the Vaginal Fluid of Women With Severe COVID-19 Infection. *Clin Infect Dis* 2020; **71**(15): 813-7.

83. Chu J, Yang N, Wei Y, et al. Clinical characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China. *J Med Virol* 2020; **92**(7): 807-13.

84. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. *J Med Virol* 2020.

85. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci* 2020; **63**(5): 706-11.

86. Li W, Cui H, Li K, Fang Y, Li S. Chest computed tomography in children with COVID-19 respiratory infection. *Pediatr Radiol* 2020; **50**(6): 796-9.

87. Wang F, Nie J, Wang H, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. *J Infect Dis* 2020; **221**(11): 1762-9.

88. Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *J Infect* 2020; **80**(6): 639-45.

89. Xu YH, Dong JH, An WM, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. *J Infect* 2020; **80**(4): 394-400.

90. Zhang MQ, Wang XH, Chen YL, et al. [Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing]. *Zhonghua Jie He He Hu Xi Za Zhi* 2020; **43**(3): 215-8.

91. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. *Ann Palliat Med* 2020; **9**(2): 428-36.

92. Tolia VM, Chan TC, Castillo EM. Preliminary Results of Initial Testing for Coronavirus (COVID-19) in the Emergency Department. *West J Emerg Med* 2020; **21**(3): 503-6.

93. Lo IL, Lio CF, Cheong HH, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. *Int J Biol Sci* 2020; **16**(10): 1698-707.

94. Huang G, Gong T, Wang G, et al. Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers the Highest and Last CT Scores From Sequential Chest CT. *AJR Am J Roentgenol* 2020; **215**(2): 367-73.

95. Gou FX, Zhang XS, Yao JX, et al. [Epidemiological characteristics of COVID-19 in Gansu province]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; **41**(0): E032.

96. Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, et al. Clinical features of the first cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain. *Travel Med Infect Dis* 2020; **35**: 101653.

97. Cao J, Tu WJ, Cheng W, et al. Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis* 2020; **71**(15): 748-55.

98. Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy* 2020; **75**(7): 1742-52.

99. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut* 2020; **69**(6): 1002-9.

100. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020; **5**(7): 811-8.

101. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev* 2020: e3319.

102. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020; **368**: m1091.

103. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. *N Engl J Med* 2020; **382**(21): 2012-22.

104. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020; **130**(5): 2620-9.

105. Tang X, Du RH, Wang R, et al. Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1. *Chest* 2020; **158**(1): 195-205.

106. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. *JAMA Oncol* 2020; **6**(7): 1108-10.

107. Li K, Fang Y, Li W, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). *Eur Radiol* 2020; **30**(8): 4407-16.

108. Iwasawa T, Sato M, Yamaya T, et al. Ultra-high-resolution computed tomography can demonstrate alveolar collapse in novel coronavirus (COVID-19) pneumonia. *Jpn J Radiol* 2020; **38**(5): 394-8.

109. Wang R, Liao C, He H, et al. COVID-19 in Hemodialysis Patients: A Report of 5 Cases. *Am J Kidney Dis* 2020; **76**(1): 141-3.

110. Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *Lancet Infect Dis* 2020; **20**(6): 697-706.

111. Zheng C, Wang J, Guo H, et al. Risk-adapted Treatment Strategy For COVID-19 Patients. *Int J Infect Dis* 2020; **94**: 74-7.

112. Zhang Y, Cao W, Xiao M, et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. *Zhonghua Xue Ye Xue Za Zhi* 2020; **41**(0): E006.

113. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. *Respir Res* 2020; **21**(1): 74.

114. Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. *Inflamm Res* 2020; **69**(6): 599-606.

115. Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). *J Intern Med* 2020; **288**(1): 128-38.

116. Wong HYF, Lam HYS, Fong AH, et al. Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19. *Radiology* 2020; **296**(2): E72-E8.

117. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis* 2020; **20**(6): 689-96.

118. Zheng F, Liao C, Fan QH, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. *Curr Med Sci* 2020; **40**(2): 275-80.

119. Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. *Int J Infect Dis* 2020; **94**: 81-7.

120. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Ann Oncol* 2020; **31**(7): 894-901.

121. Zhou Z, Guo D, Li C, et al. Coronavirus disease 2019: initial chest CT findings. *Eur Radiol* 2020; **30**(8): 4398-406.

122. Liu M, Song Z, Xiao K. High-Resolution Computed Tomography Manifestations of 5 Pediatric Patients With 2019 Novel Coronavirus. *J Comput Assist Tomogr* 2020; **44**(3): 311-3.

123. Wang K, Kang S, Tian R, Zhang X, Zhang X, Wang Y. Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area. *Clin Radiol* 2020; **75**(5): 341-7.

124. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. *Liver Int* 2020; **40**(6): 1321-6.

125. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. *J Med Virol* 2020; **92**(7): 797-806.

126. Lu T, Pu H. Computed Tomography Manifestations of 5 Cases of the Novel Coronavirus Disease 2019 (COVID-19) Pneumonia From Patients Outside Wuhan. *J Thorac Imaging* 2020; **35**(3): W90-W3.

127. Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019. *Allergy* 2020; **75**(7): 1699-709.

128. Albano D, Bertagna F, Bertoli M, et al. Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region. *J Nucl Med* 2020; **61**(5): 632-6.

129. Zhu T, Wang Y, Zhou S, Zhang N, Xia L. A Comparative Study of Chest Computed Tomography Features in Young and Older Adults With Corona Virus Disease (COVID-19). *J Thorac Imaging* 2020; **35**(4): W97-W101.

130. Yu P, Zhu J, Zhang Z, Han Y. A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period. *J Infect Dis* 2020; **221**(11): 1757-61.

131. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). *Radiology* 2020; **295**(3): 715-21.

132. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**(10223): 507-13.

133. Chen X, Yang Y, Huang M, et al. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: A retrospective study from a single center. *J Med Virol* 2020.

134. Diao K, Han P, Pang T, Li Y, Yang Z. HRCT imaging features in representative imported cases of 2019 novel coronavirus pneumonia. *Precision Clinical Medicine* 2020; **3**(1): 9-13.

135. Chen Z, Fan H, Cai J, et al. High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages. *Eur J Radiol* 2020; **126**: 108972.

136. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020; **395**(10223): 514-23.

137. Luo S, Zhang X, Xu H. Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19). *Clin Gastroenterol Hepatol* 2020; **18**(7): 1636-7.

138. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020; **180**(7): 934-43.

139. 傅京力. 李龙黄郭吴周. Clinical Characteristics of 80 Patients with COVID-19 in Zhuzhou City. *中国感染控制杂志* 2020; **19**(3): 227-33.

140. CHEN Xing OJ, HUANG Ying, TAN Mingkai, CHEN Jiabin, LIN Luping, LIANG Zhiwei, SHI Yaling. iagnostic roles of several parameters in corona virus disease 2019. *Labratory Medicine* 2020; **35**(4): 295-9.

141. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* 2020; **55**: 102763.

142. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *Int Immunopharmacol* 2020; **84**: 106504.

143. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**(15): 458-64.

144. Chen YS, Lili; Pang, XiaoHua; Mou, HuaMing; Wang, JianBing; Lang, ChunHui; Lyu, JingLong; Sun, Kai; Li, WenFa; Xiao, KaiHu. Clinical features of coronavirus disease 2019 in northeast area of Chongqing: analysis of 143 cases. *Journal of Third Military Medical University* 2020; **42**(06): 549-54.

145. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020; **369**: m1985.

146. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020; **323**(16): 1574-81.

147. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020; **323**(20): 2052-9.

148. LU Yunfei YZ, WANG Mei,SHI Jia,WANG Zhenwei,LYU Ying,TANG Bozong,YE Chen,XU Qingnian,YIN Keshan. Analysis on Chinese medical clinical characteristics of 50 patients with novel coronavirus-infected pneumonia. *Academic Journal of Shanghai University of Traditional Chinese Medicine* 2020; **34**(2): 1-5.

149. Wang J, Liu J, Wang Y, et al. [Dynamic changes of chest CT imaging in patients with corona virus disease-19 (COVID-19)]. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 2020; **49**(1): 191-7.

150. 李小虎;潘红利;束晶苇;钱银锋;吴兴旺;王海宝;李晓舒;束宏敏;李仁民;刘咸英;王玉萍;刘斌;余永强. 输入性新型冠状病毒肺炎临床和CT特征. *中国医学影像技术2020年第02期* 2020; **36**: 248-51.

151. 钟飞扬, 张寒菲, 王彬宸, 安文婷, 廖美焱. 新型冠状病毒肺炎的 CT 影像学表现. *武汉大学学报 (医学版)* 2020; (3): 1.

152. 庄英杰, 陈竹, 李进, et al. 26 例新型冠状病毒肺炎确诊病例临床和流行病学特征. *中华医院感染学杂志* 2020; (6): 8.

153. 孙宏源, 毕颖斐, 朱振刚, et al. 天津地区 88 例新型冠状病毒肺炎患者中医证候特征初探. *中医杂志* 2020; **61**(10): 837-41.

154. Technology CDLYTPaHoWUoSa. 连花清瘟颗粒治疗54例新型冠状病毒肺炎患者临床分析及典型病例报道. *世界中医药* 2020; **15**: 150-4.

155. XIANG Tianxin LJ, XU Fei, CHENG Na, LIU Yang, QIAN Kejian, ZHANG Wei. Analysis of clinical characteristics of 49 patients with coronavirus disease 2019 in Jaingxi. *Chinese Journal of Respiratory and Critical Care Medicine* 2020; **19**: 154-60.

156. Xiong J, Jiang W, Zhou Q, Hu X, Liu C. Clinical characteristics, treatment, and prognosis in 89 cases of COVID-19. *Medical Journal of Wuhan University* 2020.

157. Min FLZQCWZCFXGCLZYFF. Ｒetrospective analysis on 308 cases of COVID-19 and clinical application protocol of Kangyi Qiangshen Gong exercise prescription. *SH．J．TCM* 2020; **54**: 40-5.

158. CHENG Kebin WM, SHEN Hong, WU Chaomin,CHEN Dechang, XIONG Weining, ZHOU Xin, ZHANG Dingyu, ZHENG Junhua . Clinical characteristics of 463 patients with common and severe type coronavirus disease 2019. *Shanghai Medical Journal* 2020.

159. CHEN Tian JZ, XU Wei, ZHANG Qing Clinical features and CT imaging analysis of 76 patiens with Corona Virus Disease 2019. *Journal of Jinan University* 2020.

160. Cheng J, Huang C, Zhang G, et al. Epidemiological characteristics of novel coronavirus pneumonia in Henan. *Zhonghua jie he he hu xi za zhi= Zhonghua Jiehe he Huxi Zazhi= Chinese Journal of Tuberculosis and Respiratory Diseases* 2020; **43**: E027-E.

161. Xu S, Hu H, Hu Y, Shui H. Clinical features of 62 cases of coronavirus disease 2019 complicated with acute renal injury. *Med J Wuhan Univ* 2020: 537-41.

162. Sun W, Ling F, Pan J, et al. Epidemiological characteristics of 2019 novel coronavirus family clustering in Zhejiang Province. *Zhonghua yu Fang yi xue za zhi [Chinese Journal of Preventive Medicine]* 2020; **54**: E027-E.

163. 余思邈, 崔延飞, 王仲霞, et al. 新型冠状病毒肺炎患者 40 例临床特点与舌象关系研究. *北京中医药* 2020; **39**(2): 111-4.

164. Team C-NIRS. COVID-19, Australia: Epidemiology Report 6 (Reporting week ending 19:00 AEDT 7 March 2020). *Commun Dis Intell (2018)* 2020; **44**.

165. Lin M, Beliavsky A, Katz K, et al. What can early Canadian experience screening for COVID-19 teach us about how to prepare for a pandemic? *CMAJ* 2020; **192**(12): E314-E8.

166. Du W, Yu J, Wang H, et al. Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China. *Infection* 2020; **48**(3): 445-52.

167. Ma H, Hu J, Tian J, et al. A single-center, retrospective study of COVID-19 features in children: a descriptive investigation. *BMC Med* 2020; **18**(1): 123.

168. Li H, Chen K, Liu M, Xu H, Xu Q. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia. *J Infect* 2020; **81**(1): 115-20.

169. Song W, Li J, Zou N, Guan W, Pan J, Xu W. Clinical features of pediatric patients with coronavirus disease (COVID-19). *J Clin Virol* 2020; **127**: 104377.

170. 杜永浩, 金晨望, 杨健, et al. 家庭聚集性早期新型冠状病毒肺炎的临床与 CT 表现初步探讨. *西安交通大学学报 (医学版)* 2020; (2): 16.

171. 马耀玲, 夏胜英, 王敏, 张思敏, 杜文辉, 陈琼. 115 例新型冠状病毒感染儿童的临床特点分析. *中国当代儿科杂志* 2020; **22**(4): 290-3.

172. Zhang B, Liu S, Zhang J, et al. Children hospitalized for coronavirus disease 2019 (COVID-19): A multicenter retrospective descriptive study. *J Infect* 2020; **81**(2): e74-e5.

173. 谭鑫, 黄娟, 赵芬, 周燕, 李洁琼, 王香云. 长沙市儿童新型冠状病毒感染 13 例临床特征分析. *中国当代儿科杂志* 2020; **22**(4): 294-8.

174. Wu Q, Xing Y, Shi L, et al. Coinfection and Other Clinical Characteristics of COVID-19 in Children. *Pediatrics* 2020; **146**(1).

175. Li B, Shen J, Li L, Yu C. Radiographic and Clinical Features of Children With Coronavirus Disease (COVID-19) Pneumonia. *Indian Pediatr* 2020; **57**(5): 423-6.

176. Parri N, Lenge M, Buonsenso D, Coronavirus Infection in Pediatric Emergency Departments Research G. Children with Covid-19 in Pediatric Emergency Departments in Italy. *N Engl J Med* 2020; **383**(2): 187-90.

177. Garazzino S, Montagnani C, Dona D, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. *Euro Surveill* 2020; **25**(18).

178. Covid-19 National Emergency Response Center E, Case Management Team KCfDC, Prevention. Coronavirus Disease-19: The First 7,755 Cases in the Republic of Korea. *Osong Public Health Res Perspect* 2020; **11**(2): 85-90.

179. Chang, Lin M, Wei L, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. *JAMA* 2020; **323**(11): 1092-3.

180. Tan YP, Tan BY, Pan J, Wu J, Zeng SZ, Wei HY. Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China. *J Clin Virol* 2020; **127**: 104353.

181. Cao W. Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei. *medRxiv* 2020: 2020.02.23.20026963.

182. Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. *Am J Respir Crit Care Med* 2020; **201**(11): 1380-8.

183. 高璐, 张静平, 杜永浩, et al. 输入性新型冠状病毒肺炎的 CT 表现. *西安交通大学学报: 医学版* 2020; **41**(2): 187-.

184. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. *Eur Rev Med Pharmacol Sci* 2020; **24**(6): 3404-10.

185. Lian J, Jin X, Hao S, et al. Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. *Clin Infect Dis* 2020; **71**(15): 740-7.

186. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol* 2020; **5**(7): 802-10.

187. Yang S, Shi Y, Lu H, et al. Clinical and CT features of early stage patients with COVID-19: a retrospective analysis of imported cases in Shanghai, China. *Eur Respir J* 2020; **55**(4).

188. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. *Chin Med J (Engl)* 2020; **133**(11): 1261-7.